Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases
Description
The presentation focuses on innovative treatment strategies for dermatomyositis, particularly in cases that have failed standard therapies. Initial successes using the Janus kinase (JAK) inhibitor tofacitinib for adults and children with recalcitrant dermatomyositis are discussed, demonstrating significant improvements in skin lesions and overall disease management. The importance of recognizing MDA5 dermatomyositis through its clinical features is stressed, with successful treatment outcomes shared. Case studies outline the critical need for timely malignancy screening in patients with dermatomyositis, emphasizing risk factors such as age, cutaneous ulcers, refractory disease, and specific antibody profiles. New guidelines for cancer screening in dermatomyositis patients are highlighted, advocating for both basic and enhanced screening due to the high association between the disease and underlying malignancies. The presentation concludes with an optimistic note about collaborative treatment approaches integrating oncologists and rheumatologists, enhancing patient outcomes in the context of cancer-associated dermatomyositis.
View moreConclusions
- Tofacitinib shows significant improvement in skin lesions and pruritus for patients with refractory dermatomyositis.
- A decrease of 12 points in the CDASI score indicates clinically significant improvement in dermatomyositis patient outcomes.
- Children metabolize Jack inhibitors differently, and may require higher dosages for effective treatment.
- Interferon gene signatures correlate with disease severity in dermatomyositis patients, indicating potential pathways for targeted therapies.
- New medications targeting the interferon signaling pathway are necessary for patients still experiencing active disease despite current treatments.
- Implementing rigorous cancer screening protocols is crucial due to the high risk of malignancy in dermatomyositis patients, especially those with certain red flags.
- Patients with severe dysphagia or extensive skin lesions benefit from enhanced cancer screening strategies.
- The presence of anti-TIF1y and anti-NXP2 antibodies, along with high disease activity, should prompt immediate cancer screenings in dermatomyositis patients.
- Kurtzman DJ, Vleugels RA et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol. 2016 Aug 1;152(8):944-5.
- Leung DG, Gutierrez-Alamillo L, Perin J, et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol. 2021 May;73(5):858-865.
- Min, Vleugels et al. Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022 Feb;86(2):423-425.
- Vleugels R, Greenberg J. Interferon gene signature in dermatomyositis correlates with cutaneous disease activity (CDASI). Br J Dermatol. 2017 May;176(5):1224-1230.
- Tabata S, Fiorentino DF, et al. Interferon gene signature in dermatomyositis correlates with cutaneous disease activity (CDASI). Arthritis Rheumatol. 2023 Oct;75(10):1842-1849.
- Thomas C, Vaidya A, Kwiatkowski DJ, Rao DA, Vleugels RA. Facing Uncertainty. N Engl J Med 2019; 381:e39.
- Oldroyd A, Tansley S, Vleugels R, Werth VP, Aggarwal R. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023 Dec;19(12):805-817.